TACI haploinsufficiency protects against BAFF-driven humoral autoimmunity in mice

Eur J Immunol. 2021 Sep;51(9):2225-2236. doi: 10.1002/eji.202149244. Epub 2021 Jun 27.

Abstract

Polymorphisms in TACI, a BAFF family cytokine receptor, are linked to diverse human immune disorders including common variable immunodeficiency (CVID) and systemic lupus erythematosus (SLE). Functional studies of individual variants show modest impacts on surface TACI expression and/or downstream signal transduction, indicating that relatively subtle variation in TACI activity can impact human B-cell biology. However, significant complexity underlies TACI biology, including both positive and negative regulation of physiologic and pathogenic B-cell responses. To model these contradictory events, we compared the functional impact of TACI deletion on separate models of murine SLE driven by T cell-independent and -dependent breaks in B-cell tolerance. First, we studied whether reduced surface TACI expression was sufficient to protect against progressive BAFF-mediated systemic autoimmunity. Strikingly, despite a relatively modest impact on surface TACI levels, TACI haploinsufficiency markedly reduced pathogenic RNA-associated autoantibody titers and conferred long-term protection from BAFF-driven lupus nephritis. In contrast, B cell-intrinsic TACI deletion exerted a limited impact of autoantibody generation in murine lupus characterized by spontaneous germinal center formation and T cell-dependent humoral autoimmunity. Together, these combined data provide new insights into TACI biology and highlight how TACI signals must be tightly regulated during protective and pathogenic B-cell responses.

Keywords: B cells; BAFF; TACI; autoantibody; autoimmunity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Autoimmunity / genetics*
  • Autoimmunity / immunology
  • B-Cell Activating Factor / antagonists & inhibitors
  • B-Cell Activating Factor / genetics
  • B-Cell Activating Factor / immunology*
  • B-Cell Activation Factor Receptor / genetics
  • B-Lymphocytes / immunology
  • Chimera
  • Female
  • Haploinsufficiency / genetics
  • Immunosuppressive Agents / pharmacology
  • Lupus Nephritis / genetics*
  • Lupus Nephritis / immunology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Signal Transduction / genetics
  • Signal Transduction / immunology
  • Transmembrane Activator and CAML Interactor Protein / genetics*
  • Transmembrane Activator and CAML Interactor Protein / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • B-Cell Activating Factor
  • B-Cell Activation Factor Receptor
  • Immunosuppressive Agents
  • Tnfrsf13b protein, mouse
  • Tnfrsf13c protein, mouse
  • Tnfsf13b protein, mouse
  • Transmembrane Activator and CAML Interactor Protein
  • belimumab